Current Oncology Reports

, Volume 13, Issue 2, pp 112–119 | Cite as

Sipuleucel-T: Prototype for Development of Anti-tumor Vaccines

Article

Abstract

Prostate cancer immunotherapy officially debuted with the recent FDA approval of Sipuleucel-T. The novel trend of cancer immunotherapy relies on the identification of particular tumor-associated antigens, like prostatic acid phosphatase (PAP). Sipuleucel-T consists of autologous dendritic cells activated in vitro with recombinant fusion protein PA2024, PAP-linked to granulocyte-macrophage colony-stimulating factor. Sipuleucel-T represents a prototype for the development of cancer vaccines. Preclinical and clinical data as well as landmark studies for the existing narrow chemotherapy alternatives and early immunotherapy trials will be discussed. The pivotal trial demonstrated a 4.1-month difference of median survival, but with no effect on time to progression in asymptomatic or minimally symptomatic metastatic castrate-resistant patients. Several immunologic effects were observed in the treated population, including antibody and T cell–specific activity to P2024 and PAP. With all new therapies the extent of clinical and objective benefits versus encountered limitations should be evaluated. This review highlights the events and decisions in the process of the development of Sipuleucel-T. We discuss how this successful immunotherapy outcome challenges us to use it as a starting point for variations to or try to amplify practical anticancer progress within the antitumor vaccine paradigm.

Keywords

Dendritic cell vaccine Vaccines Immunotherapy Prostate cancer PAP-GM-CSF fusion protein 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• O'Day S, Hodi FS, McDermott DF, et al. A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol 2010, 28:18s: abstract# 4. This positive phase 3 trial showed that ipilimumab alone or combined with immunotherapy resulted in a significant improvement in OS. Ipilimumab trial is open for prostate cancer patients. Google Scholar
  2. 2.
    National clinical trial website. Available at www.clinicaltrials.gov. NCT 01057810–Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer.
  3. 3.
    •• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM 2010, 5:411–22. This is the pivotal trial that showed a difference in the median survival as well as immunologic effects in the treated population, including antibody and T cell–specific activity to P2024 and PAP. This has the most definitive dataset. CrossRefGoogle Scholar
  4. 4.
    Small EJ, Schellhammer PF, Higano CS et al. Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer. J Clin Oncol 2006, 24:3089–94.PubMedCrossRefGoogle Scholar
  5. 5.
    • Higano CS, Schellhammer PF, Small EJ, Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer. Cancer 2009,115(16):3670–79. This paper aggregates the data from two phase 3 trials with sipuleucel-T. PubMedCrossRefGoogle Scholar
  6. 6.
    Burch PA, Breen JK, Buckner JC, et al. Priming Tissue-specific Cellular Immunity in a Phase I Trial of Autologous Dendritic Cells for Prostate Cancer. Clinical Cancer Research 2000, 6: 2175–82.PubMedGoogle Scholar
  7. 7.
    • Drake CG, Antonarakis ES. Update: Immunological Strategies for Prostate Cancer. Curr Urol Rep 2010, 11:202–07. This is a recent review of prostate cancer immunotherapy. PubMedCrossRefGoogle Scholar
  8. 8.
    Almand B, Clark JI, Nikitina E et al. Increase production of immature myeloid cells in cancer patients: a mechanism of immnosuppression in cancer. The Journal of Immunology 2001, 166: 678–89.PubMedGoogle Scholar
  9. 9.
    Fishman M. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin Biol Ther 2009, 9(12):1565–75.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhang H, Melamed J, Wei P et al. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immunity 2003.3:2PubMedGoogle Scholar
  11. 11.
    Sanda MG, Restifo NP, Walsh JC et al. Molecular Characterization of Defective Antigen Processing in Human Prostate Cancer. J Natl Cancer Inst 1995; 87(4):280–85.PubMedCrossRefGoogle Scholar
  12. 12.
    Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009, 114(8): 1545–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114(8):1537–44.PubMedCrossRefGoogle Scholar
  14. 14.
    Chappell DB, Restifo NP. T cell–tumor cell: a fatal interaction? Cancer Immunol Immunother 1998, 47(2):65–71.PubMedCrossRefGoogle Scholar
  15. 15.
    Nefedova Y, Fishman M, Sherman S, el al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007, 67(22):11021–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Curti A, Trabanelli S, Salvestrini V, et al. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 2009, 113(11): 2394–2401.PubMedCrossRefGoogle Scholar
  17. 17.
    Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nature Reviews Cancer 2006, 6:521–534.PubMedCrossRefGoogle Scholar
  18. 18.
    Lahdenranta J, Hagendoorn J, Padera TP et al. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res 2009, 69(7):2801–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Deandreon company: product information available at www.provenge.com
  20. 20.
    • Stewart FP, DelaRosa CP, Sheikh N et al. Correlation between product parameters and overall survival in 3 trials of Sipuleucel-T, an Autologous Cellular Immunotherapy for the treatment of Prostate Cancer. abstract #4552 Presented at ASCO Annual Meeting 2010 Chicago, Illinois; June 4–8, 2010. This article presents how the difference in quantification of CD54+ dendritic cells in the apheresis product versus the ready-to-ship sipuleucel-T product correlates with overall survival. Google Scholar
  21. 21.
    Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.PubMedCrossRefGoogle Scholar
  22. 22.
    Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Tannock IF, de Wit R, Berry WR, Horti J et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. NEJM 2004;351(15):1502–12.PubMedCrossRefGoogle Scholar
  24. 24.
    Bubley GJ, Carducci M, Dahut W, et al. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17(11): 3461–67.PubMedGoogle Scholar
  25. 25.
    • Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial. J Clin Oncol 2009; 27(32): 5431–5438. Data presented in this trial showed that satraplatin offers PSA response, tumor regression, and improved median time to progression in pretreated patients, but with no OS increment. PubMedCrossRefGoogle Scholar
  26. 26.
    Kelly WK, Halabi S, Carducci MA et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer: Survival results of CALGB 90401. J Clin Oncol 2010; 28:18s. abstract LBA4511.Google Scholar
  27. 27.
    Beer TM, Ryan CW, Venner PM, et al. Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators. J Clin Oncol 2007;25(6):669–74.PubMedCrossRefGoogle Scholar
  28. 28.
    Scher HI, Chi KN, De Wit R, et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone for patients with progressive castration-resistant prostate cancer: Results from the phase III ASCENT2 trial. J Clin Oncol 2010; 28:15s:abstract # 4509.Google Scholar
  29. 29.
    Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells. J Clin Oncol 2000;18(23):3894–3903.PubMedGoogle Scholar
  30. 30.
    Higano C, Saad F, Somer B et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. Abstract LBA150. Presented at 2009 Genitourinary Cancers Symposium Orlando, Florida; Feb 26–28, 2009.Google Scholar
  31. 31.
    Small E, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. Abstract 7. Presented at 2009 Genitourinary Cancers Symposium Orlando, Florida; Feb 26–28,2009.Google Scholar
  32. 32.
    National clinical trial website. Available at www.clinicaltrials.gov. NCT 01057810—A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating DCVax(Tm)-Prostate, Autologous Dendritic Cells Loaded With Recombinant PSMA for the Treatment of Metastatic Hormone Refractory Prostate Cancer
  33. 33.
    • De Bono JS, Oudard S, Ozguroglu M, et al; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376(9747):1147–54. This article shows the clinical antitumor activity and improved overall survival that this new tubulin-binding taxane drug has in CRPC. PubMedCrossRefGoogle Scholar
  34. 34.
    • Peethambaram PP, Melisko ME, Rinn KJ, et al. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res. 2009;15(18):5937–44. This is an extension of the sipuleucel-T platform to another antigen. PubMedCrossRefGoogle Scholar
  35. 35.
    Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372(9633):145–54.PubMedCrossRefGoogle Scholar
  36. 36.
    Doehn C, Richter A, Theodor RA, et al. An adjuvant vaccination with Reniale prolongs survival in patients with renal cell carcinoma following radical nephrectomy: secondary analysis of a multicenter phase III trial. European Urology Supplements 2006; 5(2);286.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Moffitt Cancer Center and Research InstituteTampaUSA

Personalised recommendations